23 Feb HEALIOS K.K.
Richard Kincaid, Executive Officer and Chief Finance Officer
HEALIOS K.K. is a Japan-based, world leader in regenerative medicine. Healios researches and develops regenerative medicine products in both the somatic stem cell and induced pluripotent stem cell (iPSC) fields. Healios combines expertise and resources in iPS cells, gene-editing, and cell manufacturing technology to bring therapies and cures to patients with intractable diseases. Healios is currently conducting two pivotal clinical studies in Japan, to commercialize a somatic stem cell product to treat ischemic stroke and acute respiratory distress syndrome (ARDS). In addition, Healios has established a next generation immuno-privileged universal donor iPSC platform to advance therapies in several domains including immuno-oncology, ophthalmology, and organ buds.